title: Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia.
authors.affiliation: Cardiology, Cardiac Surgery, Intensive Care, Microbiology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Villa
authors.forename: E
authors.initials: E
authors.lastname: Lage
authors.forename: S
authors.initials: S
authors.lastname: Ballesteros
authors.forename: E
authors.initials: E
authors.lastname: Cañas
authors.forename: M
authors.initials: M
authors.lastname: Sánchez
authors.forename: A
authors.initials: A
authors.lastname: Ordóñez
authors.forename: J M
authors.initials: JM
authors.lastname: Borrego
authors.forename: R
authors.initials: R
authors.lastname: Hinojosa
authors.forename: J M
authors.initials: JM
authors.lastname: Cisneros
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000627:therapeutic use*; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D018579:Patient Selection; D010750:Phosphoproteins / Q000097:blood*; D011183:Postoperative Complications / Q000517:prevention & control / Q000821:virology; D011446:Prospective Studies; D013997:Time Factors; D014763:Viral Matrix Proteins / Q000097:blood*
chemical_list: D000998:Antiviral Agents; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa; D015774:Ganciclovir